Business Context and Reporting Period
Whitehawk Therapeutics, Inc. (WHWK) filed a Form 8-K on May 12, 2026, reporting the entry into a Material Definitive Agreement. The Company, a Delaware corporation headquartered in Pacific Palisades, California, announced a Private Investment in Public Equity (PIPE) financing intended to close on May 14, 2026.
Key Financial Metrics and Transaction Details
The filing details a capital raise with the following specific metrics:
- Total Aggregate Purchase Price: $87,500,000
- Common Stock Issuance: 4,330,866 shares at $3.92 per share
- Pre-Funded Warrants Issuance: 17,991,021 warrants at $3.9199 per warrant
- Insider Participation: Executive officers, affiliated funds of directors, and a director committed to purchasing $39,750,000 of the securities.
- Placement Agents: Jefferies LLC, Leerink Partners LLC, Oppenheimer & Co. Inc., Citizens JMP Securities, LLC, and JonesTrading Institutional Services LLC.
The filing does not provide current revenue, profit, cash flow, or debt figures, as this is a transactional report rather than a periodic financial statement.
Material Changes and Transaction Structure
The primary material change is the execution of the Securities Purchase Agreement. Key structural terms include:
- Warrant Terms: Pre-Funded Warrants have an exercise price of $0.0001, are immediately exercisable, and remain exercisable until fully exercised.
- Beneficial Ownership Limits: Holders cannot exercise warrants if it would result in beneficial ownership exceeding 4.99%, 9.99%, or 19.99% (at the holder's election) of outstanding shares immediately post-exercise. These limits can be adjusted with 61 days' prior notice.
- Lock-Up Agreements: Executive officers and directors are subject to a 60-day lock-up period following the closing of the financing.
- Registration Rights: The Company intends to file a resale registration statement within 30 days of closing and use commercially reasonable efforts to have it declared effective within 60 days (or 90 days if reviewed by the SEC).
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the expected closing date and use of proceeds, which are subject to customary closing conditions. The Company highlighted several risks that could cause actual results to differ from expectations:
- Closing Risk: The financing is contingent on the satisfaction of customary closing conditions.
- Operational Risks: Potential delays in clinical trial commencement, enrollment, and completion; dependence on third-party manufacturers; and supply chain disruptions.
- Regulatory and Scientific Risks: Unexpected adverse side effects, inadequate efficacy, regulatory developments, and the risk that early clinical results may not predict future outcomes.
- Capital Risk: The potential for capital resources to be used sooner than expected.
Investor Verification Checklist
- Verify the actual closing of the PIPE Financing on or around May 14, 2026.
- Confirm the final number of shares issued and the total net proceeds after placement fees and expenses.
- Review the filed Registration Rights Agreement (Exhibit 10.2) for specific indemnification and acceleration clauses.
- Monitor the filing of the resale registration statement within the 30-day post-closing window.
- Assess the impact of the 60-day lock-up period on future share liquidity and potential selling pressure.